for severe SLE. These medications should be continued through surgery. There were no new data available to update this recommendation, so the guidance reflects the concern about disease flares and the risk of organ damage in severe SLE that could be precipitated by medication withdrawal; although postoperative adverse events are linked to disease severity, they have not been clearly associated with medication use. As noted in the previous guideline, the patient's rheumatologist should be